Yale’s immunological and inflammatory disease therapy developer has filed for an offering with an $86.3m placeholder target.
Vera Therapeutics, a US-based immunological and inflammatory disease therapy developer spun out of Yale University, has filed for an $86.3m initial public offering.
Founded in 2016, Vera is developing therapies for the treatment of immunological and inflammatory diseases. Its lead drug candidate, atacicept, blocks the production of antibodies that contribute to certain autoimmune diseases.
Atacicept was licensed from pharmaceutical firm Merck Group and is currently undergoing a 2b clinical trial in patients with immunoglobulin A nephropathy, a kidney…
